WOLVERINE showed a benefit with MDT for oligometastatic prostate cancer in progression-free survival, radiological progression-free survival, and castration resistance-free survival. Overall survival benefit was not significant and further research is needed.
[Articles] Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration
The Lancet Oncology | | Chad Tang, Alex D Sherry, Hyunsoo Hwang, David P Farris, Giulio Francolini, Vanessa Di Cataldo, Lorenzo Livi, Phuoc Tran, Paul G Corn, Ana Aparicio, Gabriele Simontacchi, Ana P Kiess, Jarey H Wang, Valerie Fonteyne, Renee Bultijnck, Ryan Phillips, Matthew P Deek, Robert Olson, Stephen Harrow, Giulia Marvaso, Chiara Lorubbio, Barbara A Jereczek-Fossa, Ethan B Ludmir, Pierre Blanchard, Andrew Warner, Ryan Sun, David A Palma, Piet Ost
Topics: prostate-cancer, blood-cancer, clinical-trials, research